SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces CStone Pharmaceuticals (“CStone”, HKEX: 2616) recently reported that its OmniAb-derived anti-PD-L1 mAb CS1001 ...
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials In a Cox regression ...
LION-PAW: Lymphadenectomy in ovarian neoplasm-pleasure ability of women—Prospective substudy of the randomized multicenter LION study.
CS1001 is the first anti-PD-L1 mAb to demonstrate overwhelming efficacy as First Line treatment of Stage IV squamous and non-squamous NSCLC in a randomized, double-blind Phase 3 trial CS1001 combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback